👤 Yu-Lin Li

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
3991
Articles
2551
Name variants
Also published as: Xiaofeng Li, Jingwen Li, Jiajia Li, Zhaolun Li, Litao Li, Ruyi Li, Xiaocun Li, Jianyu Li, Wanxin Li, Jinsong Li, Xinzhi Li, Guanqiao Li, Ying-Lan Li, Zequn Li, Yulin Li, Shaojian Li, Guang-Xi Li, Yubo Li, Bugao Li, Mohan Li, Qingchao Li, Yan-Xue Li, Xikun Li, Enhong Li, Guobin Li, Hong-Tao Li, Xiangnan Li, Yong-Jun Li, Ziming Li, Rongqing Li, Hang Li, Xihao Li, Jing-Ming Li, Chang-Da Li, Meng-Yue Li, Yuanchang Li, DaZhuang Li, Yicun Li, Xiao-Lin Li, Jiajie Li, Zhao-Yang Li, Shunqin Li, Xinjia Li, K-L Li, Yaqiong Li, Bin Li, Yuan-hao Li, Jianhai Li, Youran Li, Peiwu Li, Yongmei Li, Changyu Li, Ran Li, Peilin Li, X Y Li, Chunshan Li, Yixiang Li, Ming Zhou Li, Ye Li, Guanglve Li, Z Li, Zili Li, Xinmei Li, Yihao Li, Liling Li, Qing Run Li, Wulan Li, Meng-Yang Li, Ziyun Li, Haoxian Li, Xiaozhao Li, Jun-Ying Li, Da-Lei Li, Xinhai Li, Yongjiang Li, Wanru Li, Jinming Li, Huihui Li, Wenhao Li, Qiankun Li, Kailong Li, Shengxu Li, Shisheng Li, Sai Li, Guangwen Li, Hua Li, Xiuli Li, Yulong Li, Dongmei Li, Ru-Hao Li, Lanzhou Li, Zhi-Peng Li, Tingsong Li, Binjun Li, Chen Li, Jiayang Li, Yawei Li, Zunjiang Li, Chao Bo Li, Minglong Li, Donghua Li, Wenzhe Li, Siming Li, Fengli Li, Song Li, Zihan Li, Hsin-Hua Li, Jin-Long Li, Hongxin Li, Dongfeng Li, You Li, Xuelin Li, Xueyang Li, Fa-Hui Li, Caiyu Li, Zhen-Yuan Li, Guangpu Li, Teng Li, Wen-Jie Li, Ang Li, Hegen Li, Zhizong Li, Lu-Yun Li, Peng Li, Shiyu Li, Bao Li, Yin Li, Cai-Hong Li, Fang Li, Jiuke Li, Miyang Li, Mingxu Li, Chen-Xi Li, Panlong Li, Dejun Li, Changwei Li, Biyu Li, Yufeng Li, Miaoxin Li, San-Feng Li, Yaoqi Li, Hu Li, Bei Li, Sha Li, W H Li, Jiaming Li, Jiyuan Li, Ya-Qiang Li, Rongkai Li, Yani Li, Xiushen Li, Jinlin Li, Xiaoqing Li, Linke Li, Shuaicheng Li, C Y Li, Thomas Li, Siting Li, Xuebiao Li, Yingyi Li, Maolin Li, Yongnan Li, Jiyang Li, Jinchen Li, Jin-Ping Li, Xuewen Li, Zhongxuan Li, R Li, Xianlong Li, Aixin Li, Linting Li, Zhong-Xin Li, Xuening Li, Enhao Li, Guang Li, Xiaoming Li, Shengliang Li, Yongli Li, Z-H Li, Baohong Li, Hujie Li, Yue-Ming Li, Shuyuan Li, Zhaohan Li, L Li, Yuanmei Li, Alexander Li, Yanwu Li, Hualing Li, Wen-juan Li, Sibing Li, Qinghe Li, Xining Li, Pilong Li, Yun-Peng Li, Zonghua Li, C X Li, Huanan Li, Jingya Li, Liqin Li, Youjun Li, Zheng-Dao Li, Miao X Li, Zhenshu Li, KeZhong Li, Heng-Zhen Li, Linying Li, Chu-Qiao Li, Fa-Hong Li, Changzheng Li, Yuhui Li, Wei Li, Wen-Ying Li, Yaokun Li, Shuanglong Li, Zhi-Gang Li, Yufan Li, Liangqian Li, Guanghui Li, Xiongfeng Li, Fei-feng Li, Letai Li, Ming Li, Kangli Li, Runwen Li, Wenbo Li, Yarong Li, Side Li, Weidong Li, S E Li, Timmy Li, Xin-Tao Li, Ruotong Li, Xiuzhen Li, Shuguang Li, Lingxi Li, Chuan-Hai Li, Qiuya Li, Jiezhen Li, Haitao Li, Tingting Li, Guanghua Li, Yufen Li, Zhongyu Li, Qin Li, Zhen-Yu Li, Deyu Li, Hansen Li, Annie Li, Wenge Li, Jinzhi Li, Xueren Li, Chun-Mei Li, Yijing Li, Kaifeng Li, Wen-Xing Li, Meng-Yao Li, Chung-I Li, Zhi-Bin Li, Qintong Li, Xiao Li, Junping Li, PeiQi Li, Naishi Li, Xiaobing Li, Liangdong Li, Xin-Ping Li, Yan Li, Han-Ni Li, Shengchao A Li, Pan Li, Jiaying Li, Ruonan Li, Cui-lan Li, Jun-Jie Li, Shuhao Li, Ruitong Li, Huiqiong Li, Guigang Li, Lucia M Li, Chunzhu Li, Suyan Li, Chengquan Li, Zexu Li, Gen-Lin Li, Dianjie Li, Zhilei Li, Junhui Li, Tiantian Li, Xue Cheng Li, Ya-Jun Li, Wenyong Li, Ding-Biao Li, Desen Li, Tianjun Li, Yansong Li, Xiying Li, Zihao Li, Weiyong Li, Xinyang Li, Fadi Li, Huawei Li, Yu-quan Li, Cui Li, Xiaoyong Li, Y L Li, Xueyi Li, Jingxiang Li, Wenxue Li, Jihua Li, Jingping Li, Zhiquan Li, Zeyu Li, Yingpu Li, Jianglin Li, Jing-Yao Li, Yan-Hua Li, Zongdi Li, Ming V Li, Shawn Shun-Cheng Li, Aowen Li, Xiao-Min Li, Ya-Ting Li, Wan Jie Li, L K Li, Dongbiao Li, Aimin Li, Tiehua Li, Keguo Li, Yuanfei Li, Longhui Li, Jing-Yi Li, Zhonghua Li, Guohong Li, Chunyi Li, Botao Li, Peiyun Li, Xiuqi Li, L-Y Li, Qinglan Li, Zhenhua Li, Zhengda Li, Haotong Li, Yue-Ting Li, Luhan Li, Da Li, Yuancong Li, Yuxiu Li, Tian Li, YiPing Li, Beibei Li, Haipeng Li, Demin Li, Chuan Li, Ze-An Li, Changhong Li, Jianmin Li, Yu Li, Minhui Li, Yvonne Li, Yiwei Li, Jiayuan Li, Xiangzhe Li, Zhichao Li, Siguang Li, Minglun Li, Yige Li, Chengqian Li, Weiye Li, Xue-Min Li, Kenneth Kai Wang Li, Dong-fei Li, Xiangchun Li, Chiyang Li, Chunlan Li, Hulun Li, Juan-Juan Li, Hua-Zhong Li, Hailong Li, Kun-Peng Li, Jiaomei Li, Haijun Li, Jing Li, Xiangyun Li, Si Li, Ji-Feng Li, Yingshuo Li, Wanqian Li, Baixing Li, Dengke Li, Zijing Li, Yuchuan Li, Wentao Li, Qingling Li, Rui-Han Li, Xuhong Li, Hongyun Li, Dong Li, Zhonggen Li, Xiong Li, Penghui Li, Xiaoxia Li, Dezhi Li, Huiting Li, Xiaolong Li, Linqing Li, Jiawei Li, Sheng-Jie Li, Defa Li, Ying-Qing Li, X L Li, Yuyan Li, Kawah Li, Xin-Jian Li, Guangxi Li, Yanhui Li, Zhenfei Li, Shupeng Li, Sha-Sha Li, Panyuan Li, Ziyu Li, Gang Li, Mengxuan Li, Hong-Wen Li, Zhuo Li, Han-Wei Li, Xiaojuan Li, Weina Li, Xiao-Hui Li, Huaiyuan Li, Dongnan Li, Rui-Fang Li, Jianzhong Li, Huaping Li, Ji-Liang Li, C H Li, Bohua Li, Bing Li, Pei-Ying Li, Huihuang Li, Shaobin Li, Yunmin Li, Yanying Li, Ronald Li, Gui Lin Li, Chenrui Li, Shi-Hong Li, Shilun Li, John Zhong Li, Xinyu Li, Song-Chao Li, Lujiao Li, Chenghong Li, Dengfeng Li, Nianfu Li, Baohua Li, N Li, Xiaotong Li, Chensheng Li, Ming-Qing Li, Yongxue Li, Bao-Shan Li, Jiao Li, Zhimei Li, Jun-Cheng Li, Yimeng Li, Jingming Li, Jinxia Li, De-Tao Li, Chunting Li, Shu Li, Julia Li, Chien-Feng Li, Huilan Li, Mei-Zhen Li, Xin-Ya Li, Zhengjie Li, Chunsheng Li, Liwei Li, Yan-Yan Li, Huijun Li, Chengyun Li, Chengjian Li, Ying-na Li, Guihua Li, Zhiyuan Li, Lijun Li, Supeng Li, Hening Li, Yiju Li, Yuanhe Li, Guangxiao Li, Fengxia Li, Xueqin Li, Peixin Li, Feng-Feng Li, Zu-Ling Li, Jialing Li, Xin Li, Yunjiu Li, Zonghong Li, Dayong Li, Ningyan Li, Lingjiang Li, Yuhan Li, Zhenghui Li, Fuyuan Li, Ailing Li, H-F Li, Chunxia Li, Chaochen Li, Zhen-Li Li, Tengyan Li, Xianlu Li, Jiaqi Li, Jiabei Li, Zhengying Li, Zhaoshui Li, Yali Li, Wenjing Li, Yu-Hui Li, Jingshu Li, Chuang Li, Jiajun Li, Can Li, Zhe Li, Han-Bo Li, Stephen Li, Shuangding Li, Kaiyuan Li, Mangmang Li, Zengyang Li, Chunyan Li, Runzhen Li, Xiaopeng Li, Xi-Hai Li, MengGe Li, Anan Li, Xuezhong Li, Luying Li, Jiajv Li, Pei-Lin Li, Xiaoquan Li, Ning Li, Ruobing Li, Yanxi Li, Wan-Xin Li, Xia Li, Yongjing Li, Meitao Li, Ziqiang Li, Huayao Li, Wen-Xi Li, Shenghao Li, Huixue Li, Boxuan Li, Jiqing Li, Hehua Li, Yucheng Li, Qingyuan Li, Yongqi Li, Fengqi Li, Zhigang Li, Yuqing Li, Guiyang Li, Guo-Qiang Li, Dujuan Li, Yanbo Li, Yuying Li, Shaofei Li, Sanqiang Li, Shaoguang Li, Min-Rui Li, Hongyu Li, Guangping Li, Shuqiang Li, Dan C Li, Huashun Li, Jinxin Li, Ganggang Li, Xinrong Li, Haoqi Li, Yayu Li, Handong Li, Huaixing Li, Yan-Nan Li, Xianglong Li, Minyue Li, Hong-Mei Li, Jing-Jing Li, Songhan Li, Conglin Li, Mengxia Li, Jutang Li, Qingli Li, Yongxiang Li, Miao Li, Songlin Li, Qilong Li, Dijie Li, Chenyu Li, Yizhe Li, Ke Li, Yan Bing Li, Jiani Li, Lianjian Li, Zhen-Hua Li, Yiliang Li, Chuan-Yun Li, Xinpeng Li, Hongxing Li, Wanyi Li, Gaoyuan Li, Youming Li, Mi Li, Dong-Yun Li, Qingrun Li, Guo Li, Jingxia Li, Xiu-Ling Li, Fuhai Li, Ruijia Li, Shuangfei Li, Fengfeng Li, Yumiao Li, Qinggang Li, Jiexi Li, Huixia Li, Kecheng Li, Xiangjun Li, Junxu Li, Xingye Li, Junya Li, Jiang Li, Huiying Li, Shengxian Li, Qingyang Li, Yuxi Li, Chenxuan Li, Xiao-Dong Li, Xinghuan Li, Xingyu Li, Zhaoping Li, Xiaolei Li, Zhenlu Li, Wenying Li, Huilong Li, Xiao-Gang Li, Honghui Li, Cheung Li, Zhenhui Li, Xuelian Li, Zhenming Li, Chunjun Li, Shu-Fen Li, Changyan Li, Mulin Jun Li, Yinghua Li, Shangjia Li, Yanjie Li, Jingjing Li, Suhong Li, Xinping Li, Siyu Li, Chaoying Li, Qiu Li, Juanjuan Li, Xiangyan Li, Guangzhen Li, Kunlun Li, Shiyun Li, Xiaoyu Li, Yaobo Li, Shiquan Li, Mei Li, Xuewang Li, Xiangdong Li, Jifang Li, Zhenjia Li, Manjiang Li, Wan Li, Zhizhong Li, Ding Yang Li, Xiaoya Li, Xiao-Li Li, Shan Li, Shitao Li, Lijia Li, Zehan Li, Chunqiong Li, Huiliang Li, Junjun Li, Chenlong Li, Shujin Li, Hui-Long Li, Zhao-Cong Li, Zhi-Wei Li, Wenxi Li, Weining Li, Wu-Jun Li, Chang-hai Li, Bin-Kui Li, Yuqiu Li, Yumao Li, Honglian Li, Xue-Yan Li, Ya-Zhou Li, Yuan-Yuan Li, Hongyi Li, Xiang-Jun Li, Y X Li, Chia Li, Yunyun Li, Zhen-Jia Li, Fu-Rong Li, Honghua Li, Lanjuan Li, Qiuxuan Li, Xiancheng Li, Man-Zhi Li, Yanmei Li, De-Jun Li, Junxian Li, Zhihua Li, Keqing Li, Shuwen Li, Danxi Li, Minqi Li, Saijuan Li, Lingjun Li, Mimi Li, Si-Xing Li, Deheng Li, Yingjie Li, Yaodong Li, Shigang Li, Yuan-Hai Li, Lujie Li, Minghao Li, Gao-Fei Li, Minle Li, Meifen Li, Yifeng Li, Le-Le Li, Huanqing Li, Ziwen Li, Yuhang Li, Yongqiu Li, Pu-Yu Li, Jianhua Li, Chanjuan Li, Nan-Nan Li, Hongming Li, Lan-Lan Li, Shuang Li, Yanchuan Li, Lingyi Li, Wanting Li, Bai-Qiang Li, Gong-Hua Li, Zhengyu Li, Chunmiao Li, Jiong-Ming Li, Yongqiang Li, Linsheng Li, Weiguang Li, Mingyao Li, Guoqing Li, Ze Li, Xiaomeng Li, R H L Li, Yuanze Li, Yunqi Li, Yuandong Li, Guisen Li, Dongyang Li, Jinglin Li, Mingfang Li, Honglong Li, Hanmei Li, Chenmeng Li, Changcheng Li, Shiyang Li, Shiyue Li, Jianing Li, Hanbo Li, Yinggao Li, Dingshan Li, Linlin Li, Xinsheng Li, Jin-Wei Li, Cheng-Tian Li, Jin-Jiang Li, Chang Li, Zhi-Xing Li, Yaxi Li, Ming-Han Li, Wei-Ming Li, Wenchao Li, Guangyan Li, Xuesong Li, Zhaosha Li, Jiwei Li, Yongzhen Li, Chun-Quan Li, Weifeng Li, Tao Li, Sichen Li, Wenhui Li, Xiankai Li, Qingsheng Li, Yaxuan Li, Liangji Li, Yuchan Li, Lixiang Li, Tian-wang Li, Jiaxi Li, Yalin Li, Jin-Liang Li, Pei-Zhi Li, You Ran Li, Xiaoqiong Li, Guanyu Li, Jinlan Li, Yixiao Li, Huizi Li, Jianping Li, Kathy H Li, Yun-Lin Li, Yadong Li, Yuhua Li, Sujing Li, Wenzhuo Li, Xuri Li, Y Li, Deqiang Li, Caixia Li, Zipeng Li, Mingyue Li, Hongli Li, Yun Li, Mengqiu Li, Ling-Ling Li, Yanfeng Li, Yaqin Li, Yu-He Li, Shasha Li, S-C Li, Xi Li, Siyi Li, Minmin Li, Manna Li, Chengwen Li, Dawei Li, Shu-Feng Li, Haojing Li, Xun Li, Ming-Jiang Li, Zhiyu Li, Sitao Li, Ziyang Li, Qian Li, Yaochen Li, Tinghua Li, Zhenfen Li, Wenyang Li, Bohao Li, Shuo Li, Wenming Li, Mingxuan Li, Si-Ying Li, Xinyi Li, Jenny J Li, Xue-zhi Li, Anqi Li, Shuai Li, Bingsong Li, Xiaoju Li, Ting Li, Zhenyu Li, Xiaonan Li, Duan Li, Xiang-Yu Li, Lei Li, Hongde Li, Fengqing Li, Na Li, Xunjia Li, Yanchang Li, Huibo Li, Ruixia Li, Nanzhen Li, Chuanfang Li, Bingjie Li, Hongxue Li, Pengsong Li, Ruotian Li, Xiaojing Li, Xinlin Li, En-Min Li, Chunya Li, Zong-Xue Li, Yan Ning Li, Honglin Li, Yu-Ying Li, Jinhua Li, Min-jun Li, Yuanheng Li, Qian-Qian Li, Chunxiao Li, Wenli Li, Shijun Li, Mengze Li, Kuan Li, Baoguang Li, Jie-Shou Li, Kaiwei Li, Zimeng Li, Mengmeng Li, W-B Li, Huangyuan Li, Lili Li, Binkui Li, Yu-Sheng Li, Junxin Li, Wei-Jun Li, Guoyan Li, Fei-Lin Li, Junjie Li, Nuomin Li, Shulin Li, Yanyan Li, Shanglai Li, Yue Li, Taibo Li, Junqin Li, Zhongcai Li, JunBo Li, Xueying Li, Jun-Ru Li, Xiaoqi Li, Zhaobing Li, Xiucui Li, Haihua Li, Linxin Li, Jen-Ming Li, Tsai-Kun Li, Shujing Li, Chen-Chen Li, Hongquan Li, Chuan F Li, Mengyun Li, Mingna Li, Yanxiang Li, Lanlan Li, Moyi Li, Xiyun Li, Yi-Wen Li, Rulin Li, Shihong Li, Ya-Pei Li, Huifeng Li, Lijuan Li, Shengbin Li, Yuanhong Li, Zhongjie Li, Zhenbei Li, Jingyu Li, Xuewei Li, Shuangshuang Li, Long Li, Wenjia Li, Min-Dian Li, Xiatian Li, Ding-Jian Li, Hongwei Li, Danni Li, Yangxue Li, Xiao-Qiang Li, Chengnan Li, Chuanyin Li, Min Li, Zhenzhou Li, Yiqiang Li, Pengyang Li, Kun-Xin Li, Xiawei Li, Binglan Li, Zesong Li, Xiangpan Li, Yutong Li, Mingfei Li, Shuwei Li, Yingnan Li, Ge Li, Mingdan Li, Xihe Li, Xinzhong Li, Jianfeng Li, Chenyao Li, Jun-Yan Li, Dexiong Li, Rongsong Li, Boru Li, Yinxiong Li, Ruixue Li, Zemin Li, Jixi Li, Chris Li, Jicheng Li, Hong-Yu Li, Chuanning Li, Weijian Li, Changhui Li, Jiafei Li, Yingying Li, Gaizhi Li, Chien-Hsiu Li, Xiangcheng Li, Siqi Li, Dechao Li, Chunxing Li, Wenxia Li, Guoxiang Li, Ziru Li, Qiao-Xin Li, Shu-Fang Li, Huang Li, Qiusheng Li, Man Li, Juxue Li, Weiqin Li, Xinming Li, Huayin Li, Xiao-yu Li, Jianyi Li, Yongjun Li, Mengyang Li, Guo-Jian Li, Guowei Li, Chenglong Li, Xingya Li, Nan Li, Gongda Li, Yajun Li, Wei-Ping Li, Yipeng Li, Mingxing Li, Nanjun Li, Xin-Yu Li, Chunyu Li, P H Li, Jinwei Li, Xuhua Li, Yu-Xiang Li, Ranran Li, Suping Li, Long Shan Li, Yanze Li, Jason Li, Xiao-Feng Li, Monica M Li, Fengjuan Li, W Li, Xianlun Li, Qi Li, Hainan Li, Yutian Li, Xiaoli Li, Xiliang Li, Shuangmei Li, Ying-Bo Li, Fei Li, Xionghui Li, Duanbin Li, Maogui Li, Dan Li, Sumei Li, Kang Li, Hongmei Li, Peilong Li, Yinghao Li, Xu-Wei Li, Mengsen Li, Lirong Li, Quanpeng Li, Wenhong Li, Audrey Li, Yijian Li, Yajiao Li, Guang Y Li, Xianyong Li, Qilan Li, Shilan Li, Qiuhong Li, Zongyun Li, Xiao-Yun Li, Guang-Li Li, Cheng-Lin Li, Bang-Yan Li, Enxiao Li, Jianrui Li, Yousheng Li, Wen-Ting Li, Guohua Li, Kezhen Li, Guoping Li, Xingxing Li, Ellen Li, A Li, Simin Li, Xue-Nan Li, Weiguo Li, Yijie Li, Xiaoying Li, Suwei Li, Shengsheng Li, Shuyu D Li, Ruiwen Li, Jiandong Li, Fangyong Li, Hong Li, Binru Li, Yuqi Li, Zihua Li, Yuchao Li, Hanlu Li, Jianang Li, Xue-Peng Li, Qing Li, Jiaping Li, Sheng-Tien Li, Yazhou Li, Shihao Li, Jun-Ling Li, Caesar Z Li, Feng Li, Weiyang Li, Peihong Li, Lang Li, Jin-Mei Li, Lisha Li, Feifei Li, Kejuan Li, Qinghong Li, Qiqiong Li, Cuicui Li, Kaibo Li, Xinxiu Li, Chongyi Li, Yi-Ying Li, Hanbing Li, Shaodan Li, Meng-Hua Li, Yongzheng Li, Da-Hong Li, J T Li, Xiao-mei Li, Jiejie Li, Ruihuan Li, Xiangwei Li, Baiqiang Li, Ziliang Li, Yaoyao Li, Mo Li, Yueguo Li, Ming-Hao Li, Zheng Li, Donghe Li, Congfa Li, Wenrui Li, Hongsen Li, Yong Li, Xiuling Li, Menghua Li, Jingqi Li, Ka Li, Kaixin Li, Fuping Li, Zhiyong Li, Jianbo Li, Xing-Wang Li, Chong Li, Xiao-Kang Li, Fugen Li, Hanqi Li, Yangyang Li, Yuwei Li, Dongfang Li, Xiaochen Li, Zizhuo Li, Zhuorong Li, X-H Li, Xianrui Li, Lan-Juan Li, Dong Sheng Li, Zhigao Li, Chenlin Li, Zihui Li, Xiaoxiao Li, Guoli Li, Le-Ying Li, Pengcui Li, Xiaoman Li, Huanqiu Li, Bing-Heng Li, Zhan Li, Weisong Li, Xinglong Li, Xiaohong Li, Xiaozhen Li, Yuan Hao Li, Jianchun Li, Wenxiang Li, Zhaoliang Li, Guo-Ping Li, Zhiyang Li, Cunxi Li, Jinhui Li, Zhifei Li, Ying Li, Yanshu Li, Jianlin Li, Yuanyou Li, Chongyang Li, Yumin Li, Wanyan Li, Jinku Li, Guiying Li, Longyu Li, X B Li, Changgui Li, Zhisheng Li, Cuiling Li, Xuekun Li, Yuguang Li, Wenke Li, Jianguo Li, Jiayi Li, En Li, Ximei Li, Shaoyong Li, Peihua Li, Kai-Wen Li, Suwen Li, Chang-Ping Li, Guangda Li, Yixue Li, Guandu Li, Junfeng Li, Xin-Chang Li, Jieming Li, Kongdong Li, Yue-Ying Li, Chunhui Li, Peiyu Li, Tongyao Li, Lian Li, Linfeng Li, Yuzhe Li, Xinmiao Li, Chenyang Li, Jiacheng Li, Xiaohua Li, Chang-Yan Li, Qifang Li, Vivian Li, Duanxiang Li, Xiaolin Li, Meiting Li, Justin Li, Xue-Er Li, Zhuangzhuang Li, Xiaohui Li, Hongchang Li, Cang Li, Xuepeng Li, Youwei Li, Mingjiang Li, Ronggui Li, Xingwang Li, Tiange Li, Yongjia Li, Dacheng Li, Xinmin Li, Zongyu Li, Luquan Li, Jianyong Li, Guoxing Li, Shujie Li, Zongchao Li, Yanbin Li, Jia Li, Shiliang Li, Haimin Li, Qinrui Li, Sheng-Qing Li, Yiming Li, Lingjie Li, Xiao-Tong Li, Yiwen Li, Tie Li, Baoqi Li, Wei-Bo Li, Leyao Li, Xiaoyi Li, Liyan Li, Xiao-Qin Li, Xiaokun Li, Xinke Li, Ming-Wei Li, Wenfeng Li, Minzhe Li, Jiajing Li, Karen Li, Yanlin Li, X Li, Liao-Yuan Li, Meifang Li, Yanjing Li, Yongkai Li, Maosheng Li, Ju-Rong Li, Jin Li, Shibo Li, Hangwen Li, Li-Na Li, Hengguo Li, An-Qi Li, Xuehua Li, Hui Li, AnHai Li, Chenli Li, Rumei Li, Zhengrui Li, Fangqi Li, Xiaoguang Li, Xian Li, Danjie Li, Yan-Yu Li, Vivian S W Li, Lipeng Li, Qinghua Li, Qinqin Li, Leilei Li, Ranchang Li, Defu Li, Lianyong Li, Amy Li, Zhou Li, Q Li, Haoyu Li, Xiaoyao Li, M-J Li, Jiao-Jiao Li, Rongling Li, Zhu Li, Tong-Ruei Li, Bizhi Li, Cheng-Wei Li, Wenwen Li, Guangqiang Li, Jian'an Li, Ben Li, Sichong Li, Wenyi Li, Yingxia Li, Meiyan Li, Qing-Min Li, Yonghe Li, Yun-Da Li, Xinwei Li, Yu-I Li, Shunhua Li, Mingxi Li, Jian-Qiang Li, Yingrui Li, Chenfeng Li, Qionghua Li, Guo-Li Li, Xingchen Li, Ziqi Li, Shen Li, Tianjiao Li, Gui-Rong Li, Shufen Li, Yunfeng Li, Yueqi Li, Yunpeng Li, Qiong Li, Xiao-Guang Li, Jiali Li, Zhencheng Li, Qiufeng Li, Songyu Li, Xu Li, Pinghua Li, Shi-Fang Li, Shude Li, Yaxiong Li, Zhibin Li, Zhenli Li, Qing-Fang Li, Rosa J W Li, Yunxiao Li, Hsin-Yun Li, Shengwen Li, Gui-Bo Li, XiaoQiu Li, Xueer Li, Zhi Li, Zhankui Li, Zihai Li, Yue-Jia Li, Haihong Li, Peifen Li, Taixu Li, Mingzhou Li, Jiejing Li, Meng-Miao Li, Meiying Li, Chunlian Li, Meng Li, Zhijie Li, Cun Li, Huimin Li, Ruifang Li, T Li, Xiao-xu Li, Man-Xiang Li, Yinghui Li, Cong Li, Chengbin Li, Feilong Li, Yuping Li, Sin-Lun Li, Mengfan Li, Weiling Li, Jie Li, Shiyan Li, Lianbing Li, G Li, Yanchun Li, Xuze Li, Zhi-Yong Li, Yukun Li, Jialin Li, Wenjian Li, He Li, Bichun Li, Xiong Bing Li, Hanqin Li, Qingjie Li, Wen Lan Li, Guoge Li, Han Li, Wen-Wen Li, Keying Li, Yutang Li, Minze Li, Xingcheng Li, Wanshun Li, Congxin Li, Hankun Li, Hongling Li, Xiangrui Li, Caolong Li, Chaojie Li, Michelle Li, Zhifan Li, J Li, Zhi-Jian Li, Jianwei Li, Yan-Guang Li, Jiexin Li, Hongyan Li, Ji-Min Li, Zhen-Xi Li, Guangdi Li, Peipei Li, Tian-Yi Li, Xiaxia Li, Yuefeng Li, Nien Li, Zhihao Li, Peiyuan Li, Yao Li, Zheyun Li, Tiansen Li, Chi-Yuan Li, Xiangfei Li, Xue Li, Zhonglin Li, Fen Li, Lin Li, Jieshou Li, Chenjie Li, Jinfang Li, Roger Li, Yanming Li, Hong-Lan Li, Mengqing Li, S L Li, Ben-Shang Li, Ming-Kai Li, Shunqing Li, Xionghao Li, Lan Li, Menglu Li, Huiqing Li, Yanwei Li, Yantao Li, Chien-Te Li, Wenyan Li, Xiaoheng Li, Zeyuan Li, Ruolin Li, Yongle Li, Hongqin Li, Zhenhao Li, Jonathan Z Li, Haying Li, Shao-Dan Li, Muzi Li, Yong-Liang Li, Gen Li, Dong-Ling Li, M Li, Chenwen Li, Jiehan Li, Le Li, Hongguo Li, Yong-Jian Li, Chenxin Li, Yongsen Li, Qingyun Li, Pengyu Li, Si-Wei Li, Ai-Qin Li, Zichao Li, Manru Li, Yingxi Li, Caili Li, Yuqian Li, Guannan Li, Wei-Dong Li, Cien Li, Qingyu Li, Xijing Li, Jingshang Li, Xingyuan Li, Dehua Li, Wenlong Li, Ya-Feng Li, Yanjiao Li, Jia-Huan Li, Yuna Li, Xudong Li, Guoxi Li, Xingfang Li, Shengli Li, Shugang Li, Jisheng Li, Rongyao Li, Xuan Li, Yongze Li, Ru Li, Yongxin Li, Lu Li, Jiangya Li, Yiche Li, Yilang Li, Zhuo-Rong Li, Bingbing Li, Qinglin Li, Runzhi Li, Yunshen Li, Jingchun Li, Qi-Jing Li, Hexin Li, Zhenyan Li, H J Li, Yanping Li, Ji Xia Li, Meizi Li, Yu-Ye Li, Qing-Wei Li, Qiang Li, Yuezheng Li, Hsiao-Hui Li, L I Li, Zhengnan Li, Jianglong Li, Hongzheng Li, Laiqing Li, Zhongxia Li, Ningyang Li, Guangquan Li, Xiaozheng Li, Hui-Jun Li, Shun Li, Guojun Li, Xuefei Li, Senlin Li, Hung Li, Jinping Li, Sainan Li, Huili Li, Jinghui Li, Zulong Li, Chengsi Li, P Li, Hongzhe K Li, Fulun Li, Xiao-Qiu Li, Jiejia Li, Yonghao Li, Mingli Li, Yehong Li, Zhihui Li, Yi-Yang Li, Fujun Li, Pei Li, Quanshun Li, Yongping Li, Liguo Li, Ni Li, Weimin Li, Mingxia Li, Xue-Hua Li, M V Li, Luxuan Li, Qiang-Ming Li, Yakui Li, Huafu Li, Xinye Li, Gan Li, Shichao Li, Chunliang Li, Ruiyang Li, Dapei Li, Zejian Li, Lihong Li, Chun Li, Jianan Li, Wenfang Li, Haixia Li, Sung-Chou Li, Xiangling Li, Lianhong Li, Jingmei Li, Ao Li, Yitong Li, Siwen Li, Yanlong Li, Cheng Li, Kui Li, Zhao Li, Tiegang Li, Yunxu Li, Shuang-Ling Li, Zhong Li, Xiao-Long Li, Hung-Yuan Li, Xiaofei Li, Xuanfei Li, Zilin Li, Zhang Li, Jianxin Li, Mingqiang Li, H Li, Xiaojiao Li, Dongliang Li, Chenxiao Li, Yinzhen Li, Hongjia Li, Li-Min Li, Xiao-Jing Li, Yunsheng Li, Xiangqi Li, Jian Li, Y H Li, Jia-Peng Li, Baichuan Li, Daoyuan Li, Haibo Li, Wenqi Li, Zhenzhe Li, Xiao-Jun Li, Jian-Mei Li, Kaimi Li, Yan-Hong Li, Peiran Li, Shi Li, Xueling Li, Qiao Li, Yi-Yun Li, Xiao-Cheng Li, Conghui Li, Xiaoxiong Li, Wanni Li, Yike Li, Chitao Li, Yihan Li, Haiyang Li, Jiayu Li, Xiaobai Li, Junsheng Li, Pingping Li, Mingquan Li, Wen-Ya Li, Suran Li, Yunlun Li, Rongxia Li, Yuanfang Li, Yingqin Li, Guoqin Li, Qiner Li, Huiqin Li, Shanhang Li, Jiafang Li, Chunlin Li, Han-Bing Li, Zongzhe Li, Yikang Li, Jisen Li, Si-Yuan Li, Caihong Li, Hongmin Li, Yajing Li, Peng Peng Li, Kenli Li, Guanglu Li, Benyi Li, Yuquan Li, Xiushi Li, Hongzhi Li, Jian-Jun Li, Dongmin Li, Fengyi Li, Yanling Li, Chengxin Li, Juanni Li, Xiaojiaoyang Li, C Li, Jian-Shuang Li, Xinxin Li, You-Mei Li, Yubin Li, Chenglan Li, Dazhi Li, Beixu Li, Yuhong Li, Di Li, Fengqiao Li, Guiyuan Li, Yanbing Li, Suk-Yee Li, Jufang Li, Yuanyuan Li, Shengjie Li, Xiaona Li, Shanyi Li, Hongbo Li, Chih-Chi Li, Xinhui Li, Zecai Li, Qipei Li, Xiaoning Li, Jun Li, Minghua Li, Xiyue Li, Tianchang Li, Zhuoran Li, Hongru Li, Shiqi Li, Mei-Ya Li, Wuyan Li, Mingzhe Li, Yi-Ling Li, Hongjuan Li, Yingjian Li, Zhirong Li, Wang Li, Mingyang Li, Weijun Li, Boyang Li, Senmao Li, Cai Li, Mingjie Li, Ling-Jie Li, Hong-Chun Li, Jingcheng Li, Ivan Li, Yaying Li, Mengshi Li, Liqun Li, Manxia Li, Ya Li, Changxian Li, Dan-Ni Li, Wen-Chao Li, Sunan Li, Zhencong Li, Chunqing Li, Jiong Li, Lai K Li, Yanni Li, Daiyue Li, Bingong Li, Huifang Li, Xiujuan Li, Yongsheng Li, Lingling Li, Chunxue Li, Yunlong Li, Xinhua Li, Jianshuang Li, Juanling Li, Minerva X Li, Xinbin Li, Alexander H Li, Xue-jing Li, Yuling Li, Wendeng Li, Ding Li, Yetian Li, Xianlin Li, Chuangpeng Li, Mingrui Li, Shengze Li, Ming-Yang Li, Linyan Li, Yanjun Li, Jiequn Li, Zhongding Li, Hewei Li, Da-Jin Li, Jiangui Li, Zhengyang Li, Cyril Li, Xinghui Li, Yuefei Li, Xiao-kun Li, Xinyan Li, Yuanhao Li, Xiaoyun Li, Congcong Li, Ji-Lin Li, Ping'an Li, Yushan Li, Juan Li, Huan Li, Weiping Li, Changjiang Li, Chengping Li, G-P Li, He-Zhen Li, Xiaobin Li, Shaoqi Li, Yinliang Li, Yuehua Li, Jinfeng Li, Wen Li, Shiheng Li, Weihai Li, Hsiao-Fen Li, Jiangan Li, Yu-Kun Li, Zhaojin Li, Mengjiao Li, Bingxin Li, Wenjuan Li, Wenyu Li, Chia-Yang Li, Meng-Meng Li, Tianxiang Li, Liangkui Li, Tian-chang Li, Hairong Li, Yahui Li, Su Li, Xi-Xi Li, Wenlei Li, Mei-Lan Li, Wenjun Li, Jiaxin Li, Haiyan Li, Ming D Li, Chenguang Li, Ruyue Li, Xujun Li, Chi-Ming Li, Xiaolian Li, Dandan Li, Yi-Ning Li, Yunan Li, Zhijun Li, Zechuan Li, Jiazhou Li, Sherly X Li, Wanling Li, Ya-Ge Li, Yinyan Li, Qijun Li, Rujia Li, Guangli Li, Lixia Li, Zhiwei Li, Xueshan Li, Yunrui Li, Yuhuang Li, Shanshan Li, Jiangbo Li, Xiaohan Li, Wan-Shan Li, Zhongwen Li, Huijie Li, W W Li, Yalan Li, Yiyang Li, Jing-gao Li, Xuejun Li, Fengxiang Li, Nana Li, Shunwang Li, Yaqing Li, Chao Li, Yaqiao Li, Jingui Li, Bingsheng Li, Huamao Li, Xiankun Li, Jingke Li, Tianyao Li, Xiaowei Li, Junming Li, Jianfang Li, Shubo Li, Qi-Fu Li, Zi-Zhan Li, Hai-Yun Li, Haoran Li, Zhongxian Li, Xiaoliang Li, Xinyuan Li, Maoquan Li, H-J Li, Zhixiong Li, Chumei Li, Shijie Li, Lingyan Li, Zhanquan Li, Wenguo Li, Fangyuan Li, Xuhang Li, Xiaochun Li, Chen-Lu Li, Xinjian Li, Jialun Li, Rui Li, Zilu Li, Xuemin Li, Sheng-Fu Li, Zezhi Li, Xue-Fei Li, Yudong Li, Shanpeng Li, Hongjiang Li, Wei-Na Li, Dong-Run Li, Yunxi Li, Jingyun Li, Xuyi Li, Binghua Li, Hanjun Li, Yunchu Li, Jin-Qiu Li, Zhengyao Li, Qihua Li, Jiaxuan Li, Jinghao Li, Y-Y Li, Xiaofang Li, Tuoping Li, Pengyun Li, Guangjin Li, Lin-Feng Li, Xutong Li, Ranwei Li, Ziqing Li, Kai Li, Wei-Li Li, Keanning Li, Yongjin Li, Shuangxiu Li, Chenhao Li, Ling Li, Weizu Li, Deming Li, Peiqin Li, Xiaodong Li, Nanxing Li, Qihang Li, Jianrong Li, Baoguo Li, Zhehui Li, Chenghao Li, Jiuyi Li, Luyao Li, Chun-Xu Li, Weike Li, Desheng Li, Chuanbao Li, Long-Yan Li, Zhixuan Li, Fuyu Li, Chuzhong Li, M D Li, Lingzhi Li, Yuan-Tao Li, Kening Li, Guilan Li, Wanshi Li, Hengtong Li, Ling-Zhi Li, Yifan Li, Ya-Li Li, Xiao-Sa Li, Songyun Li, Xiaoran Li, Bolun Li, Kunlin Li, Linchuan Li, Jiachen Li, Haibin Li, Shu-Qi Li, Huangbao Li, Zehua Li, Guo-Chun Li, Xinli Li, Mengyuan Li, S Li, Wenqing Li, Wenhua Li, Caiyun Li, Xinrui Li, Congye Li, Dehai Li, Wensheng Li, Qingshang Li, Jiannan Li, Guanbin Li, Zhiyi Li, Hanbin Li, Xing Li, Wanwan Li, Jia Li Li, Zhaoyong Li, SuYun Li, Shiyi Li, Wan-Hong Li, Mingke Li, Suchun Li, Xiaoyuan Li, Huanhuan Li, Yanan Li, Zongfang Li, Yang Li, Jiayan Li, YueQiang Li, Xiangping Li, H-H Li, Jinman Li, BoWen Li, Duoyun Li, Yimei Li, Dongdong Li, Hao Li, Liliang Li, Mengxi Li, Keyuan Li, Zhi-qiang Li, Shaojing Li, S S Li, Yi-Ting Li, Jiangxia Li, Yujie Li, Tong Li, Yilong Li, Lihua Li, Xue-Lian Li, Yan-Li Li, Zhiping Li, Haiming Li, Yansen Li, Gaijie Li, Yuemei Li, Zhi-Yuan Li, Yanli Li, Jingfeng Li, Hai Li, Kaibin Li, Yuan-Jing Li, Xuefeng Li, Xiaohu Li, Wenjie Li, Ruikai Li, Mengjuan Li, Xiao-Hong Li, Yinglin Li, Yaofu Li, Ren-Ke Li, Qiyong Li, Ruixi Li, Yi Li, Baosheng Li, Zhonglian Li, Yujun Li, Mian Li, Dalin Li, Lixi Li, Jin-Xiu Li, Kun Li, Qizhai Li, Jiwen Li, Pengju Li, Peifeng Li, Zhouhua Li, Ai-Jun Li, Qingqin S Li, Honglei Li, Yueting Li, Guojin Li, Xin-Yue Li, Dingchen Li, YaJie Li, Xiaoling Li, Jixuan Li, Yanqing Li, Zijian Li, Zhandong Li, Xuejie Li, Congjiao Li, Peining Li, Meng-Jun Li, Gaizhen Li, Huilin Li, Songtao Li, Liang Li, Fusheng Li, Huafang Li, Dai Li, Meiyue Li, Chenlu Li, Keshen Li, Kechun Li, Nianyu Li, Yuxin Li, X-L Li, Shaoliang Li, Shawn S C Li, Shu-Xin Li, Hong-Zheng Li, Qun Li, Tianye Li, Cuiguang Li, Dongye Li, Zhen Li, Chunhong Li, F Li, Yuan Li, Mengling Li, Kunpeng Li, Jia-Da Li, Zhenghao Li, Chun-Bo Li, Zhantao Li, Baoqing Li, Pu Li, Xinle Li, Xingli Li, Bingkun Li, Nien-Chi Li, Wuguo Li, Tiewei Li, Bing-Hui Li, Daniel Tian Li, Rong-Bing Li, Honggang Li, Jingyong Li, Shikang Li, Wei-Yang Li, Rong Li, Mingkun Li, Binxing Li, Shi-Ying Li, Zixiao Li, Ming Xing Li, Guixin Li, Quanzhang Li, Ming-Xing Li, Marilyn Li, Da-wei Li, Hong-Lian Li, Shishi Li, Bei-Bei Li, Haitong Li, Xiumei Li, Ruibing Li, Melody M H Li, Yuli Li, Qingfang Li, Peibo Li, Qibing Li, Huanjun Li, Heng Li, Wende Li, Chung-Hao Li, Liuzheng Li, Zhanjun Li, Yifei Li, Tianming Li, Chang-Sheng Li, Xiao-Na Li, Tianyou Li, Jipeng Li, Xidan Li, Yixing Li, Chengcheng Li, Yu-Jin Li, Longxuan Li, Baoting Li, Huiyou Li, Ka Wan Li, Shi-Guang Li, Wenxiu Li, Binbin Li, Xinyao Li, Zhuang Li, Yu-Hao Li, Gui-xing Li, Shunle Li, Shilin Li, Niu Li, Siyue Li, Diyan Li, Mengyao Li, Shili Li, Yixuan Li, Shan-Shan Li, Zhuanjian Li, Meiqing Li, Gerard Li, Yuyun Li, Hengyu Li, Zhiqiong Li, Yinhao Li, Zonglin Li, Pik Yi Li, Junying Li, Jingxin Li, Mufan Li, Chun-Lai Li, Defeng Li, Shiya Li, Zu-guo Li, Xin-Zhu Li, Xiao-Jiao Li, Jia-Xin Li, Kuiliang Li, Pindong Li, Hualian Li, Youchen Li, Junhong Li, Li Li, W Y Li, Hanxue Li, Lulu Li, Yi-Heng Li, Xiaoqin Li, L P Li, Runbing Li, Chunmei Li, Mingjun Li, Yuanhua Li, Qiaolian Li, Yanmin Li, Ji-Cheng Li, Jingyi Li, Yuxiang Li, Haolong Li, Hao-Fei Li, Xuanzheng Li, Peng-li Li, Quan Li, Yining Li, Xue-Ying Li, Xiurong Li, Huijuan Li, Haiyu Li, Xu-Zhao Li, Yunze Li, Yanzhong Li, Guohui Li, Kainan Li, Yongzhe Li, Tianyi Li, Qingfeng Li, Xiaoyan Li, Nanlong Li, Ping Li, Xu-Bo Li, Nien-Chen Li, Fangzhou Li, Yue-Chun Li, Jiahui Li, Huiping Li, Kangyuan Li, Biao Li, Yuanchuang Li, Haiying Li, Yunting Li, Xiaoxuan Li, Anyao Li, Qing-Chang Li, Hongliang Li, Shengbiao Li, Hong-Yan Li, Yue-Rui Li, Ruidong Li, Dalei Li, Zongjun Li, Y M Li, Changqing Li, Hanting Li, Dong-Jie Li, Sijie Li, Dengxiong Li, Xiaomin Li, Meilan Li, D C Li, Andrew C Li, Jianye Li, Yi-Shuan J Li, Tinghao Li, Qiuyan Li, Zhouxiang Li, Tingguang Li, Yun-tian Li, Jianliang Li, Xiangyang Li, Guangzhao Li, Chunjie Li, Yixi Li, Shuyu Dan Li, S A Li, Tianfeng Li, Anna Fen-Yau Li, Minghui Li, Jiangfeng Li, Jinjie Li, Liming Li, Jie-Pin Li, Junyi Li, Kaiyi Li, Wenqun Li, Dongtao Li, Fengyuan Li, Guixia Li, Yinan Li, Aoxi Li, Zuo-Lin Li, Chenxi Li, Yuanjing Li, Zhengwei Li, Linqi Li, Bingjue Li, Xixi Li, Binghu Li, Yan-Chun Li, Suiyan Li, Yu-Hang Li, Qiaoqiao Li, Zhenguang Li, Xiaotian Li, Jia-Ru Li, Shuhui Li, Chun-Xiao Li, Pei-Qin Li, Shu-Hong Li, Shuyue Li, Mengying Li, Tongzheng Li, Fangyan Li, Quan-Zhong Li, Yihong Li, Duo Li, Dali Li, Yaxian Li, Zhiming Li, Xuemei Li, Xueting Li, Hongxia Li, Yongting Li, Zhenjun Li, Danyang Li, Ren Li, Tiandong Li, Lanfang Li, Hongye Li, Mingwei Li, Di-Jie Li, Bo Li, Jinliang Li, Wenxin Li, W J Li, Qiji Li, Zhijia Li, Zhipeng Li, Xiaoping Li, Jingtong Li, Linhong Li, Taoyingnan Li, Lucy Li, Lieyou Li, Zhengpeng Li, Xiayu Li, Huabin Li, Mao Li, Baolin Li, Cuilan Li, Yuting Li, Yongchao Li, Xiaoting Li, Xiaobo Li, Ruotai Li, Meijia Li, Shujiao Li, Yaojia Li, Xiao-Yao Li, Kun-Ping Li, Weirong Li, Weihua Li, Shangming Li, Yaqi Li, Yibo Li, Gui-Hua Li, Zhihong Li, Yandong Li, Runzhao Li, Chaowei Li, Xiang-Dong Li, Huiyuan Li, Yuchun Li, Yanxin Li, Yingjun Li, Xiufeng Li, Xiaohuan Li, Ying-Qin Li, Boya Li, Lamei Li, O Li, Fan Li, Jun Z Li, Suheng Li, Joyce Li, Yiheng Li, Taiwen Li, Hui-Ping Li, Xiaorong Li, Zhiqiang Li, Junru Li, Hecheng Li, Jiangchao Li, Haifeng Li, Yueping Li, Changkai Li, Liping Li, Rena Li, Jiangtao Li, Yu-Jui Li, Zhenglong Li, Yajuan Li, Xuanxuan Li, Rui-Jún Eveline Li, Bing-Mei Li, Yunman Li, Chaoqian Li, Shuhua Li, Yu-Cheng Li, Chunying Li, Yirun Li, Haomiao Li, Weiheng Li, Leipeng Li, Qianqian Li, Baizhou Li, Zhengliang Li, YiQing Li, Han-Ru Li, Wei-Qin Li, Sheng Li, Weijie Li, Guoyin Li, Yaqiang Li, Qingxian Li, Zongyi Li, Dan-Dan Li, Yeshan Li, Qiwei Li, Zirui Li, Chengjun Li, Keke Li, Yongpeng Li, Jianbin Li, Chanyuan Li, Shiying Li, Jianxiong Li, Huaying Li, Ji Li, Tuojian Li, Yixin Li, Ziyue Li, Juntong Li, Zhongzhe Li, Xiang Li, Yumei Li, Xiang-Ping Li, Chaonan Li, Wenqiang Li, Yu-Chia Li, Pei-Shan Li, Zaibo Li, Shaomin Li, Heying Li, Guangming Li, Xuan-Ling Li, Yuxuan Li, Bingshan Li, Xiaoqiang Li, Jiahao Li, Hanxiao Li, Jiansheng Li, Shuying Li, Shibao Li, Pengjie Li, Xiaomei Li, Kunlong Li, Ruijin Li
articles
Shichao Li, Liang Peng, Yuting Wang · 2026 · Actas espanolas de psiquiatria · added 2026-04-24
As a result of individual genetic variations, some patients show no response to initial antidepressant medications. This study aims to investigate the association between specific genetic polymorphism Show more
As a result of individual genetic variations, some patients show no response to initial antidepressant medications. This study aims to investigate the association between specific genetic polymorphisms and the efficacy of antidepressant drugs and to improve the accuracy and effectiveness of treatment under the guidance of genetic testing. A retrospective screening was conducted on medical records from, Suixian People's Hospital between January 2022 and December 2024. A total 202 patients with depression carrying the CYP2C19 gene were selected after the application of exclusion criteria. They were assigned to three groups in accordance with their genetic metabolism types: the rapid metabolism group (Group A, n = 65), the intermediate metabolism group (Group B, n = 94) and the poor metabolism group (Group C, n = 43). All three groups were treated with sertraline for a six-week treatment cycle. The observation indicators included scores on the Hamilton Depression Scale (HAMD); onset time of drug effect; rates of response and remission; scores on the Clinical Global Impression-Improvement (CGI-I) scale; levels of the neurotransmitter factors 5-hydroxytryptamine (5-HT), γ-aminobutyric acid (GABA) and brain-derived neurotrophic factor (BDNF); incidence of adverse events; and scores on the Morisky Medication Adherence Scale-8 (MMAS-8). The baseline data of the three groups of patients were comparable before medication (p > 0.05). Compared with those in Groups A and B, patients in Group C showed a significantly greater reduction in HAMD scores (all p < 0.05), along with higher response rates (all p < 0.05) and remission rates (all p < 0.05). Amongst the three groups, Group C had a shorter onset time of drug effect (all p < 0.05); more significant improvement in CGI-I scores (all p < 0.05); and more prominent upregulation of neurotransmitter factors, namely, 5-HT (all p < 0.05), GABA (all p < 0.05) and BDNF (all p < 0.05). Regarding the incidence of adverse events, Group C had the highest rate, whereas Group A had the lowest (10.8% vs. 24.5% vs. 41.9%). Compared with other groups, Group B exhibited a more significant increase in MMAS-8 scores (all p < 0.05). Metabolic phenotype exerts substantial effects on the therapeutic outcome of sertraline in patients with depression carrying the CYP2C19 gene. Amongst groups, Group C showed better therapeutic efficacy but an elevated incidence of adverse events and lower medication adherence; Group A had relatively poor efficacy; and Group B demonstrated superior adherence. In clinical practice, individualised treatment can be implemented on the basis of CYP2C19 metabolic typing to improve therapeutic efficacy and reduce adverse events and medical burden. Show less
📄 PDF DOI: 10.62641/aep.v54i1.2098
BDNF
Xi Zhang, Yanglin Hao, Dong Han +16 more · 2026 · Circulation · added 2026-04-24
Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification remain unclea Show more
Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification remain unclear. Here, we aimed to investigate the role of PRMT3 (protein arginine methyltransferase 3) in valvular calcification and calcific aortic valve disease progression. Both aortic valve leaflets and valvular interstitial cells from patients were used to evaluate the expression pattern and investigate the underlying mechanism of PRMT3 in calcific aortic valve disease pathogenesis. High-cholesterol diet-fed Apoe (apolipoprotein E)-deficient ( We found that PRMT3 expression was significantly upregulated during aortic valve calcification. RUNX2 (runt-related transcription factor 2) recruited P300 to promote PRMT3 expression through histone H3 lysine 27 acetylation. Moreover, We identify a previously unrecognized posttranslational mechanism regulating PCSK9 stability in valve interstitial cells during calcific aortic valve disease and establish a link between PRMT3-mediated arginine methylation and valve-specific lipid-osteogenic coupling. Show less
no PDF DOI: 10.1161/CIRCULATIONAHA.125.078830
APOE
Yuxiao Feng, Hengyun Tian, Chengcheng Hui +7 more · 2026 · European journal of pharmacology · Elsevier · added 2026-04-24
Lilium brownii is a plant that can be used for medicinal and food purposes. 1-O-p-coumaroyl-3-O-feruloyl glycerol (CF) is a phenolic acid glycerol dimer isolated from Lilium brownii. This study aims t Show more
Lilium brownii is a plant that can be used for medicinal and food purposes. 1-O-p-coumaroyl-3-O-feruloyl glycerol (CF) is a phenolic acid glycerol dimer isolated from Lilium brownii. This study aims to evaluate the neuroprotective effects of CF and elucidate the possible molecular mechanisms underlying its neuroprotective effects through in vivo and in vitro models of Parkinson's disease. 1-methyl-4-phenylpyridinium ions (MPP Following CF administration, the apoptosis rate and reactive oxygen species (ROS) levels in PC12 cells were significantly reduced. CF markedly upregulated the expression of proteins including dopamine, tyrosine hydroxylase, brain-derived neurotrophic factor (BDNF), while simultaneously downregulating the expression of proteins such as α-synuclein. Molecular docking results demonstrated favorable affinity between CF and proteins including p62. This compound not only ameliorated motor and cognitive impairments in Parkinson's disease mice but also markedly increased neuronal numbers within the substantia nigra region of these animals. CF exerts a neuroprotective effect in Parkinson's disease by modulating the p62-Keap1-Nrf2 signalling pathway. Show less
no PDF DOI: 10.1016/j.ejphar.2026.178618
BDNF biochemistry molecular biology neuroprotection neuroscience parkinson's disease phenolic acid signalling pathway
Jinlian Xie, Jie Huang, Qian Wu +10 more · 2026 · Diabetes, obesity & metabolism · Blackwell Publishing · added 2026-04-24
This first-in-human Phase I study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of KN069, a novel dual Glucagon-like peptide-1 receptor agonist (GLP-1RA)/Glucose- Show more
This first-in-human Phase I study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of KN069, a novel dual Glucagon-like peptide-1 receptor agonist (GLP-1RA)/Glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist in Chinese men with overweight/obesity. This randomised, double-blind trial included a single ascending dose (SAD; 12-120 mg, N = 36, 3:1 active-to-placebo) and a multiple ascending dose (MAD; N = 12, dose escalation 15-60 mg) phase. Safety was assessed via adverse events (AEs) and compliance. PK was analysed using a sandwich enzyme-linked immunosorbent assay (ELISA) for Intact and Total KN069. PD included measurements of body weight, waist circumference, body mass index (BMI) and metabolic parameters. Immunogenicity was assessed by detecting anti-drug antibodies (ADA). KN069 was well tolerated, with predominantly mild-to-moderate gastrointestinal adverse events. PK showed dose-proportional exposure (12-90 mg) with a long half-life for Total KN069 (899.74-1099.01 h). In the SAD part, preliminary dose-dependent weight reductions were observed, with maximum early changes at Day 7 (90 mg: -4.71% vs. placebo: -0.41%) and sustained for up to 133 days. In the MAD part, Group B (60 mg) achieved a -2.57% mean weight reduction from baseline at Day 25, alongside a significant decrease in waist circumference (p = 0.0446). Metabolic improvements included lower fasting glucose, triglycerides, uric acid and elevated insulin/C-peptide. KN069 exhibits favourable safety, long-acting PK and preliminary dose-dependent weight reduction alongside expected pharmacologic metabolic effects, supporting further clinical development. gov Identifier: NCT06547775. Show less
no PDF DOI: 10.1111/dom.70794
GIPR
Ying Zhang, Zhouting Tuo, Yuan Lin +10 more · 2026 · Cancer research · added 2026-04-24
Cancer-associated fibroblasts (CAF) are abundant stromal cells in the tumor microenvironment (TME) that play a vital role in promoting tumor progression and drug resistance. The mechanisms regulating Show more
Cancer-associated fibroblasts (CAF) are abundant stromal cells in the tumor microenvironment (TME) that play a vital role in promoting tumor progression and drug resistance. The mechanisms regulating heterogeneity of CAFs in renal cell carcinoma (RCC) could represent potential targets for reprogramming the TME. In this study, we conducted single-cell RNA sequence and flow cytometry analyses that identified a CAF subset overexpressing apolipoprotein E (ApoE), which was correlated with poor survival in patients with RCC. Mechanistically, NRF1 activation in CAFs induced formation of ApoEhigh CAFs and secretion of NRG1. ApoEhigh CAFs potentiated stemness properties in the surrounding RCC cells by secreting NRG1 and subsequently activating the HER2/NF-κB pathway. Interfering with NRG1 expression or inhibiting NF-κB signaling reduced ApoEhigh CAF-induced stemness of RCC cells. Furthermore, neutralizing NRG1 enhanced the efficacy of sunitinib in RCC models in vivo. Together, these findings highlight targeting the tumor-promoting functions of ApoEhigh CAFs as a promising approach for treating advanced RCC. NRF1 drives formation of ApoEhigh cancer-associated fibroblasts that secrete NRG1 to stimulate stemness of renal cell carcinoma, revealing a stromal-mediated mechanism that can be inhibited to improve treatment of advanced kidney cancer. Show less
no PDF DOI: 10.1158/0008-5472.CAN-25-0959
APOE
Fanrong Zeng, Xinyi Zhang, Meng Zhang +6 more · 2026 · Frontiers in endocrinology · Frontiers · added 2026-04-24
This study investigated the impact of This retrospective case-control study involved 628 CAD patients and 628 matched controls without CAD. ApoE genotyping was conducted using PCR-chip technology, and Show more
This study investigated the impact of This retrospective case-control study involved 628 CAD patients and 628 matched controls without CAD. ApoE genotyping was conducted using PCR-chip technology, and genotype and allele frequencies were compared between groups. Multivariate logistic regression analyzed the link between ApoE polymorphisms and CAD risk in populations at middle and high altitudes. The data revealed significant differences in These findings validated that the Show less
📄 PDF DOI: 10.3389/fendo.2026.1765770
APOB
Zhihao Zhao, Yutong Yang, Liu Zhang +12 more · 2026 · Scientific reports · Nature · added 2026-04-24
Pancreatic cancer (PC) is a common gastrointestinal malignancy whose initiation and progression may be closely linked to the gut microbiota. Previous research indicates that Scutellaria barbata D. Don Show more
Pancreatic cancer (PC) is a common gastrointestinal malignancy whose initiation and progression may be closely linked to the gut microbiota. Previous research indicates that Scutellaria barbata D. Don and Scleromitrion diffusum (Willd.) R.J. Wang (SB-SD) exhibit diverse biological activities, such as anti-inflammatory, antioxidant, and antitumor effects, though their precise regulatory mechanisms are not fully elucidated. Here, we treated PC cells with SB-SD to assess its impact on cell viability, apoptosis, migration, and cell cycle progression, while Western blotting analyzed the expression of HSP90AA1, MAPK3, p53, CDK1, and p21. We also established a pancreatic cancer xenograft model in nude mice to evaluate the in vivo inhibitory effect of SB-SD on tumor growth. Furthermore, we employed metagenomic sequencing, untargeted metabolomics, and quantitative proteomics to comprehensively profile changes in the gut microbiota, serum metabolites, and differentially expressed proteins, with Western blotting subsequently validating BCKDK, GATM and p53 expression. The results show that SB-SD significantly inhibited PC cell proliferation, promoted apoptosis, and induced S/G2 phase cell cycle arrest, potentially via modulation of the HSP90AA1/MAPK3 signaling pathway. Measurements of tumor volume and weight, complemented by histopathological analysis, confirmed that SB-SD effectively suppressed the growth of PANC-1 xenograft tumors. Integrated multi-omics analyses suggest that the antitumor effects of SB-SD may involve the modulation of key gut microbes like Bacteroides caccae and Lactobacillus, the promotion of choline metabolism, and the regulation of BCKDK and GATM. Together, these findings not only corroborate the direct antitumor activity of SB-SD against pancreatic cancer but also offer novel mechanistic insights by constructing a microbiota-metabolite-protein interaction network. Show less
📄 PDF DOI: 10.1038/s41598-026-45676-x
BCKDK
Dan Pan, Mingchen Jiang, Ying Wang +6 more · 2026 · Neurobiology of stress · Elsevier · added 2026-04-24
Major depressive disorder is a severe mental health condition characterized by persistent depressed mood and loss of interest. Current first-line pharmacotherapies often exhibit limited therapeutic pe Show more
Major depressive disorder is a severe mental health condition characterized by persistent depressed mood and loss of interest. Current first-line pharmacotherapies often exhibit limited therapeutic performance and adverse side effects. Transcutaneous auricular vagus nerve stimulation (taVNS) is a promising, safe, and noninvasive alternative intervention with demonstrated neuromodulatory efficacy. Nevertheless, its mechanisms remain unclear. This study investigated whether the antidepressant properties of taVNS are associated with the microbiota-gut-brain axis, focusing on the potential crosstalk between differentially expressed hippocampal proteins and the gut microbiota. A chronic unpredictable mild stress (CUMS) rat model of depression was established, and taVNS was administered for 14 days. Hippocampal proteomic profiling was performed using data-independent acquisition. Fecal metagenomic sequencing was conducted to characterize alterations in gut microbial communities. Key signaling pathways were validated using Western blot, qRT-PCR, HE staining, and transmission electron microscopy, all of which were employed to systematically assess behavioral, proteomic, microbial, and molecular changes. Proteomics and molecular analyses revealed that taVNS upregulated hippocampal expression of glutamate ionotropic receptor N-methyl-D-aspartate type subunit 1 (GluN1) and brain-derived neurotrophic factor (BDNF), while simultaneously restoring mitogen-activated protein kinase (MAPK) signaling activity. Metagenomic profiling demonstrated that taVNS increased the abundance of TaVNS significantly alleviated depression-like behaviors in CUMS-exposed rats. The underlying mechanism may involve the restoration of synaptic function of glutamatergic neurons by regulating the GluN1/MAPK/BDNF signaling pathway. In addition, taVNS reshaped the gut microbiota, markedly increasing the abundance of Show less
📄 PDF DOI: 10.1016/j.ynstr.2025.100777
BDNF
MengGe Li, HuiYue Wang, ZhenYan Tang +2 more · 2026 · Aging and disease · added 2026-04-24
The neurovascular unit (NVU) represents a multicellular functional ensemble pivotal to the preservation of cerebral homeostasis, encompassing endothelial cells, pericytes, glial cells (astrocytes, mic Show more
The neurovascular unit (NVU) represents a multicellular functional ensemble pivotal to the preservation of cerebral homeostasis, encompassing endothelial cells, pericytes, glial cells (astrocytes, microglia, oligodendrocytes), and neurons. This complex orchestrates the regulation of blood-brain barrier (BBB) integrity, cerebral blood flow (CBF), and the metabolic microenvironment requisite for neuronal viability and functional competence. Accumulating lines of evidence have underscored that NVU dysfunction constitutes a critical early pathological event in neurodegenerative disorders, including Alzheimer's disease (AD) and vascular dementia (VaD). The present review summarizes the structural composition and core physiological functionalities of the NVU, with particular emphasis on the emerging role of lipid metabolism dysregulation in mediating NVU impairment-an aberrant process encompassing lipid droplets, apolipoprotein E (APOE), ATPase phospholipid transporting 11B (ATP11B), triggering receptor expressed on myeloid cells 2 (TREM2), and ATP-binding cassette (ABC) transporters. We further delineate the mechanisms by which disrupted lipid homeostasis elicits neuroinflammation, amplifies oxidative stress, impairs amyloid-β (Aβ) clearance, and precipitates BBB breakdown, ultimately culminating in cognitive decline. Simultaneously, this review examines controversies within the field, such as the specific role of apolipoprotein E ε4 allele (APOE4) in disease and highlights the significant pathophysiological differences between preclinical animal models and human diseases. Therapeutic strategies targeting lipid metabolism or the blood-brain barrier still face considerable challenges in clinical translation. Meanwhile, emerging tools such as lipidomics contribute to systematically analyzing the associated dysregulated lipid networks, thereby aiding in the identification of novel therapeutic targets. Show less
no PDF DOI: 10.14336/AD.2025.1464
APOE
Youhai Jiang, Jianan Chen, Zhengyuan Meng +10 more · 2026 · Cancer letters · Elsevier · added 2026-04-24
The response rate to immune checkpoint blockade (ICB) in hepatocellular carcinoma (HCC) remains unsatisfactory, and the mechanisms of resistance are not fully understood. Here, we investigated the rol Show more
The response rate to immune checkpoint blockade (ICB) in hepatocellular carcinoma (HCC) remains unsatisfactory, and the mechanisms of resistance are not fully understood. Here, we investigated the role of fibroblast growth factor receptor 1 (FGFR1) in shaping the tumor microenvironment (TME) and mediating ICB resistance. An anti-PD-1-resistant HCC model was established in mice, followed by single-cell RNA sequencing to profile TME alterations. We observed that ICB resistance was associated with FGFR1 upregulation, which activated MAPK signaling and induced SPP1 expression. This cascade promotes macrophage infiltration and M2-type polarization, while simultaneously suppressing T cell recruitment and cytotoxic function, thereby fostering an immunosuppressive microenvironment. SPP1 knockdown or neutralization significantly reduced macrophage accumulation and restored intratumoral T cell infiltration. Importantly, pharmacological inhibition of FGFR1 using BGJ398 synergized with anti-PD-1 therapy, resulting in enhanced antitumor efficacy in preclinical models. Analysis of clinical datasets further revealed that high FGFR1 expression correlated with poor responses to ICB of HCC patients. Collectively, these findings identify FGFR1 as a key mediator of ICB resistance in HCC. Targeting FGFR1 represents a promising strategy to reprogram the immunosuppressive TME and enhance response to immunotherapy, with potential additional value as a predictive biomarker. Show less
no PDF DOI: 10.1016/j.canlet.2026.218361
FGFR1
Mei Zhao, Chao Zhang, Xin Zhang +3 more · 2026 · Nature communications · Nature · added 2026-04-24
Multiple sclerosis (MS) is a neurodegenerative autoimmune disease primarily mediated by T helper 17 (T
no PDF DOI: 10.1038/s41467-025-67665-w
WWP2
Ya-Xin Deng, Bao-Jun Ding, Hong-Chun Li +4 more · 2026 · Yi chuan = Hereditas · added 2026-04-24
The
no PDF DOI: 10.16288/j.yczz.25-190
APOA4
Azadeh Feizpour, Vincent Doré, Pierrick Bourgeat +24 more · 2026 · The journal of prevention of Alzheimer's disease · Elsevier · added 2026-04-24
The agreement between plasma Aβ42/40 and Aβ positron emission tomography (PET) is approximately 75 %, with ∼85 % of discrepancies due to positive plasma but negative PET results. It is unclear whether Show more
The agreement between plasma Aβ42/40 and Aβ positron emission tomography (PET) is approximately 75 %, with ∼85 % of discrepancies due to positive plasma but negative PET results. It is unclear whether this reflects Aβ changes in plasma before PET-detectable. To assess the influence of Aβ42/40 positivity on risk of progression to Aβ PET positivity, and feasibility of using plasma Aβ42/40 tests to enrich a primary prevention trial. A prospective longitudinal cohort study. Participants of Australian Imaging, Biomarkers and Lifestyle study (AIBL), Alzheimer's Disease Neuroimaging Initiative (ADNI), and Open Access Series of Imaging Studies 3 (OASIS3). 507 cognitively unimpaired adults at baseline, with a baseline Aβ PET < 20 Centiloid (CL) and available longitudinal Aβ PET data. Baseline Aβ PET and plasma Aβ42/40 measurement by mass-spectrometry, followed by 1-6 additional Aβ PET scans every 1.5-3 years. Those < 5 CL were classified as PET- and 5-20 CL as PET At baseline, 283 were Plasma-/PET-, 97 Plasma+/PET-, 76 Plasma-/PET Cognitively unimpaired individuals with abnormal Aβ42/40 are at increased risk for future Aβ PET positivity. In the 5-20 CL subgroup, baseline CL is the main driver of this risk. Combining blood-based pre-screening with PET imaging may help efficiently enrich primary prevention trials. Show less
📄 PDF DOI: 10.1016/j.tjpad.2025.100455
APOE
Qiang Li, Zhiqi Liao, Xinyao Hu +26 more · 2026 · Molecular therapy : the journal of the American Society of Gene Therapy · Elsevier · added 2026-04-24
Clinical application of mesenchymal stem cells for endometrial repair has been hampered by variability in cell quality, large-scale production, and uncertainty regarding the optimal delivery route. In Show more
Clinical application of mesenchymal stem cells for endometrial repair has been hampered by variability in cell quality, large-scale production, and uncertainty regarding the optimal delivery route. In this study, we investigated the therapeutic potential of clinical-grade human embryonic stem cell-derived immunity-and-matrix-regulatory cells (IMRCs) for treating refractory moderate-to-severe intrauterine adhesion (IUA). In a rabbit IUA model, sub-endometrial injection of IMRCs significantly reduced fibrosis and enhanced endometrial angiogenesis, outperforming uterine perfusion. Transcriptomic analysis revealed distinct pro-angiogenic gene expression profiles between the two delivery routes. In vitro, IMRCs co-cultured with endometrial stromal cells (ESCs) markedly enhanced angiogenic potential compared to either cell type alone. Protein array analysis of the co-culture supernatant showed elevated levels of angiogenic factors, with functional assays confirming that inhibition of ANGPTL4, a non-canonical pro-angiogenic mediator, impaired angiogenesis. In a first-in-human, single-center, phase 1 dose-escalation trial involving 18 patients with refractory IUA, high-dose sub-endometrial IMRC injection promoted angiogenesis, reduced uterine scarring, and improved pregnancy outcomes, with no safety concerns observed over 3 years of follow-up. These findings highlight the translational promise of IMRCs as a novel therapeutic strategy for endometrial regeneration in severe IUA. Show less
📄 PDF DOI: 10.1016/j.ymthe.2025.09.035
ANGPTL4
Yali Yang, Zhenzhong Han, Guowei Li +7 more · 2026 · Bioscience trends · added 2026-04-24
Hereditary Multiple Osteochondromas (HMO) is a rare autosomal dominant skeletal disorder caused by heterozygous loss-of-function mutations in EXT1 or EXT2, which encode glycosyltransferases essential Show more
Hereditary Multiple Osteochondromas (HMO) is a rare autosomal dominant skeletal disorder caused by heterozygous loss-of-function mutations in EXT1 or EXT2, which encode glycosyltransferases essential for heparan sulfate (HS) biosynthesis. Whether haploinsufficiency alone suffices or biallelic inactivation is required for osteochondroma formation remains a central unresolved question. In this study, we employed CRISPR/Cas9 combined with PiggyBac transposon technology to introduce a second pathogenic mutation (c.1883+1G>T) into patient-derived induced pluripotent stem cells (iPSCs) carrying a heterozygous EXT1 c.1126C>T mutation. This approach enabled the generation of isogenic iPSC lines: wild-type (WT), single-mutant (SM), and double-mutant (DM). These iPSCs were differentiated through induced mesenchymal stem cells (iMSCs) into chondrocytes. Biallelic EXT1 mutation in DM cells led to significant upregulation of SOX9, COL2A1, and ACAN, elevated glycosaminoglycan (GAG) levels, and markedly reduced HS, whereas SM cells remained indistinguishable from WT. Three-dimensional (3D) chondrogenic organoid cultures revealed that DM organoids were enlarged and structurally disorganized, partially recapitulating key histopathological features of osteochondromas. Transcriptomic analysis identified the Wnt signaling pathway as the most significantly enriched pathway among differentially expressed genes following EXT1 loss. Collectively, these findings provide direct human cellular evidence that complete EXT1 inactivation-not haploinsufficiency-drives aberrant chondrogenesis, likely through impaired sequestration of morphogen ligands, thereby supporting the Two-hit pathogenic model. Show less
no PDF DOI: 10.5582/bst.2026.01046
EXT1
Kirk W Donovan, Eric Stefan, Bekim Bajrami +12 more · 2026 · Cell chemical biology · Elsevier · added 2026-04-24
We report the discovery of a chemical series that enhances ApoE secretion from human astrocytes through mechanisms independent of LXR agonism. Target deconvolution of hits from a phenotypic screen in Show more
We report the discovery of a chemical series that enhances ApoE secretion from human astrocytes through mechanisms independent of LXR agonism. Target deconvolution of hits from a phenotypic screen in astrocytoma cells employed chemoproteomics, photoaffinity probes, in vitro KINOMEscan analysis, and targeted siRNA knockdown experiments. Photoaffinity labeling coupled with quantitative chemical proteomics identified aryl hydrocarbon receptor (AhR), a transcription factor not previously associated with ApoE secretion, as the primary target. A diverse panel of AhR agonists and antagonists together with genetic knockdown confirmed that ApoE secretion increases when AhR activity is reduced. Using a luciferase reporter assay, we demonstrated that active series analogs exhibit AhR antagonism while inactive compounds do not. Since deletion of AhR has severe peripheral effects, chronic inhibition of AhR is not an attractive therapeutic approach for Alzheimer's disease; nevertheless, these results position AhR as a modulator of ApoE secretion and a biological pathway worth exploring. Show less
no PDF DOI: 10.1016/j.chembiol.2025.12.005
APOE
Jiatong Sun, Zixuan Gao, Yuanhao Li +5 more · 2026 · Journal of hepatocellular carcinoma · added 2026-04-24
Tripartite motif-containing protein 21 (TRIM21), an E3 ubiquitin ligase of the TRIM superfamily, modulates critical cellular processes including ubiquitination, autophagy, and oxidative stress respons Show more
Tripartite motif-containing protein 21 (TRIM21), an E3 ubiquitin ligase of the TRIM superfamily, modulates critical cellular processes including ubiquitination, autophagy, and oxidative stress response. Accumulating evidence highlights its context-dependent regulatory roles in hepatocellular carcinoma (HCC)-the most prevalent primary liver malignancy with high mortality and limited therapeutic efficacy. This review systematically summarizes the core mechanisms by which TRIM21 orchestrates HCC progression: ① Autophagy regulation: TRIM21 modulates HCC autophagy via multiple axes, including CCR4-NOT complex (TNKS1BP1/CNOT4)-mediated substrate ubiquitination, ATG14-dependent autophagosome initiation, and RETREG1-driven reticulophagy, with context-dependent effects on tumor proliferation. ② Drug resistance: TRIM21 enhances oxaliplatin sensitivity by ubiquitinating and degrading G6PD (the rate-limiting enzyme of the pentose phosphate pathway), while its role in sorafenib resistance involves dual pathways-the MST1/YAP axis and the ApoE/cholesterol/PI3K-AKT cascade. ③ Metastasis suppression: TRIM21 restricts HCC invasion and metastasis by ubiquitinating key oncoproteins, preserving epithelial integrity and inhibiting mesenchymal transition. ④ Reactive oxygen species (ROS) balance: TRIM21 regulates oxidative stress in HCC via the SQSTM1/p62-Keap1-NRF2 axis, coordinating with HIF1α to modulate antioxidant responses and tumor cell survival. Additionally, we discuss the regulatory significance of TRIM21 in HCC associated with hepatitis B virus (HBV) infection (via HBx/DNA polymerase ubiquitination) and nonalcoholic steatohepatitis (NASH) (via suppressing lipogenic enzymes to reduce steatosis-driven carcinogenesis). This review provides a theoretical basis for TRIM21 as a potential diagnostic marker and therapeutic target for HCC. Show less
📄 PDF DOI: 10.2147/JHC.S575307
APOE
Chenxu Ge, Jiamao Lin, Changsheng Yang +19 more · 2026 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Wiley · added 2026-04-24
Particulate matter ≤2.5 µm (PM
📄 PDF DOI: 10.1002/advs.202508458
MC4R
Ruoyi Ishikawa, Yu Yamazaki, Nayuta Nakazawa +6 more · 2026 · Neurobiology of disease · Elsevier · added 2026-04-24
APOE polymorphisms are major genetic risk factors of Alzheimer's disease (AD). Compared with APOE3/E3, the APOE4/E4 genotype is associated with a > 14-fold increased risk. Therefore, we hypothesized t Show more
APOE polymorphisms are major genetic risk factors of Alzheimer's disease (AD). Compared with APOE3/E3, the APOE4/E4 genotype is associated with a > 14-fold increased risk. Therefore, we hypothesized that conversion of APOE4 to APOE3 would ameliorate AD-related pathologies. Accordingly, we generated a knock-in mouse model harboring an APOE4-FLEx (Flip-Excision) 4-to-3 construct enabling postnatal Cre-mediated APOE4-to-APOE3 switching. This construct comprised an APOE3 exon inserted in a reverse orientation downstream of the APOE4 exon, flanked by alternating loxP and mutant loxP sites, allowing Cre-mediated FLEx switching from APOE4-to-APOE3. For in vitro validation, HEK293T cells were transfected with APOE4-FLEx 4-to-3 plasmid, followed by AAV8-mediated iCre delivery. For in vivo studies, endogenous Apoe was replaced with the APOE4-FLEx 4-to-3 construct to generate APOE4-FLEx 4-to-3 knock-in mice, which were crossed with tamoxifen-inducible Rosa26-CreERT2 mice to yield Cre: APOE4-FLEx 4-to-3 double-knock-in mice. Tamoxifen was administered to induce APOE switching. Cre expression successfully induced APOE4-to-APOE3 switching in vitro. Tamoxifen administration in Cre: APOE4-FLEx 4-to-3 mice triggered APOE4-to-APOE3 switching in the liver, demonstrating the feasibility of postnatal isoform switching. However, brain APOE protein levels were below the detection limit. Investigation of the underlying cause involving transcript analysis revealed aberrant retention of intron 3 (APOE-I3). This abnormal splicing probably contributed to the decreased expression of fully spliced, translation-competent (mature) APOE mRNA, driving the subsequent protein reduction. Although APOE expression across organs in APOE4-FLEx 4-to-3 mice requires further optimization, our findings demonstrate that Cre-mediated FLEx switching can serve as a potential strategy to induce APOE genotype switching in vivo. Show less
no PDF DOI: 10.1016/j.nbd.2025.107244
APOE
Joshua C Rosen, Pinjiang Cao, Nhu-An Pham +13 more · 2026 · British journal of cancer · Nature · added 2026-04-24
KRAS We studied short-term changes in signaling and mechanisms of primary resistance to AZD4625 in twelve KRAS Sustained tumor regression in four (33%) PDXs was observed while the remaining eight mode Show more
KRAS We studied short-term changes in signaling and mechanisms of primary resistance to AZD4625 in twelve KRAS Sustained tumor regression in four (33%) PDXs was observed while the remaining eight models were intrinsically resistant to AZD4625. Organoid responses to AZD4625 were concordant with their derived PDXs. Acute AZD4625 exposure significantly decreased gene expression of the ERK1/2 negative regulator, DUSP6, in all models while protein MAPK and AKT/mTOR signals were downregulated more frequently in the AZD4625-sensitive than AZD4625-resistant cohorts. Analyzing PDX transcriptomes and proteomes identified mTOR signaling as a putative mechanism of primary resistance to AZD4625. Our findings confirm AZD4625 as a highly active KRAS Show less
📄 PDF DOI: 10.1038/s41416-025-03216-w
DUSP6
Yiming Li, Wenxin Zou, Yan Zhang +5 more · 2026 · Phytomedicine : international journal of phytotherapy and phytopharmacology · Elsevier · added 2026-04-24
Atherosclerosis (AS) is a chronic disease characterized by lipid deposition in the vascular intima. As the pathological basis of cardiovascular diseases, AS represents a major contributor to global mo Show more
Atherosclerosis (AS) is a chronic disease characterized by lipid deposition in the vascular intima. As the pathological basis of cardiovascular diseases, AS represents a major contributor to global morbidity and mortality. While Gualou Huoxue Jiedu Decoction (GHJD) has been widely used in clinical practice for the treatment of AS, the molecular mechanisms remain unclear. To investigate the anti-atherosclerotic effects and underlying mechanisms of GHJD. Apoe GHJD alleviated plaque formation, improved lipid metabolism, and suppressed inflammation in vivo. Multi-omics analysis revealed that DNA methylation of Mfap4 could be a pivotal target of GHJD efficacy. In vitro assays confirmed that GHJD suppressed Mfap4 transcription and translation, leading to downregulation of integrin receptor family expression and inhibition of VSMC phenotypic switching. GHJD exerts anti-atherosclerotic effects through epigenetic modulation of Mfap4 and downstream integrin/FAK signaling pathway, thereby inhibiting VSMC phenotypic switching. These findings provide pharmacological evidence supporting GHJD as a potential therapy for AS and, for the first time, validate MFAP4 as a pharmacological target, offering new insights into AS prevention and treatment. Show less
no PDF DOI: 10.1016/j.phymed.2026.157881
APOE
Xiang Xu, Yuanze Li, Siqi Xiang +3 more · 2026 · Human genomics · BioMed Central · added 2026-04-24
Atherosclerosis (AS) is a chronic vascular disease and the principal cause leading to ischemic cardiomyopathy (ICM). It involves complex metabolic dysregulation beyond the resolution of single-omics. Show more
Atherosclerosis (AS) is a chronic vascular disease and the principal cause leading to ischemic cardiomyopathy (ICM). It involves complex metabolic dysregulation beyond the resolution of single-omics. Emerging evidence implicates arginine-proline metabolism (APM) in driving inflammation and impairing efferocytosis, yet the cellular basis of plaque instability remains elusive. We employed a five-stage analytical framework. First, metabolomic profiling revealed shared pathways between AS and ICM. Second, single-cell RNA sequencing identified APM-enriched macrophage subtypes in both diseases. Pseudotime analysis, Scissor algorithm, and cell-cell communication analyses linked these subtypes to APM signaling, stroke prognosis, and key ligand-receptor interactions. Third, cNMF and unsupervised clustering defined APM-related gene signatures in macrophages, validated by survival analysis. Fourth, spatial transcriptomics confirmed their spatial distribution and colocalization within unstable plaques. Finally, key biomarkers were validated in atherosclerotic lesions using ApoE Metabolomic profiling revealed APM as a shared dysregulated pathway in AS and ICM. We identified a macrophage subset (SPP1⁺ macrophages and mono-macrophages), termed APM_high macrophages, enriched in the fibrous cap and characterized by elevated collagenase activity, heightened inflammation, and disrupted cholesterol homeostasis. Spatial and cell-cell communication analyses revealed strong interactions with dendritic cells via the MIF-(CD74 + CXCR4) axis, potentially contributing to plaque destabilization. Transcriptomic clustering uncovered a high-APM plaque subtype associated with worse ischemic outcomes. Six diagnostic biomarkers were identified through machine learning and validated across multiple cohorts and in ApoE In summary, our study decodes the metabolic basis of inflammation shared between AS and ICM, suggesting an APM_high macrophage-centered regulatory axis across multiple omics layers. This work advances our understanding of the cardio-metabolic axis and suggests new avenues for targeted therapy. Show less
📄 PDF DOI: 10.1186/s40246-025-00869-9
APOE
Shuyue Li, Jianhui Guo, Yaqi Wang +4 more · 2026 · Environmental pollution (Barking, Essex : 1987) · Elsevier · added 2026-04-24
Ambient PM
no PDF DOI: 10.1016/j.envpol.2026.127961
APOE
Feng Su, Shengnan Lu, Yaoyao Zhang +8 more · 2026 · Clinical and experimental pharmacology & physiology · Blackwell Publishing · added 2026-04-24
The presence of a blood-brain barrier (BBB) prevents the delivery of most drugs to the brain. This characteristic limitation poses a major challenge to effective pharmacological treatment for numerous Show more
The presence of a blood-brain barrier (BBB) prevents the delivery of most drugs to the brain. This characteristic limitation poses a major challenge to effective pharmacological treatment for numerous neurodegenerative diseases, particularly Alzheimer's disease. Delivering small interfering RNA (siRNA) via nanoparticles represents a highly promising approach for treating Alzheimer's disease. Nevertheless, developing a safe and efficient siRNA delivery system remains challenging. To enhance brain targeting and therapeutic efficacy, we developed an siRNA nanocarrier system based on PAH-AM-PEG-ApoE (PAPA) nanoparticles (PAPA/siRNA NPs), which facilitates BBB penetration. In this study, an siRNA nanocarrier delivery system modified with ApoE peptide (PAPA/siRNA NPs) developed by our research team was employed to simultaneously encapsulate BACE1-siRNA and GSK3β-siRNA. The PAPA/siRNA NPs were prepared through self-assembly and electrostatic binding. The particle size distribution profile and zeta potential of the PAPA/siRNA NPs were analysed with dynamic light scattering, while its morphology was examined with transmission electron microscopy. For in vitro assessments, flow cytometry, confocal laser scanning microscopy, PCR, and Western blotting were employed to evaluate the cellular uptake, gene silencing capacity, and endosomal escape. The biodistribution was investigated by in vivo imaging technology, and the therapeutic effect on AD was verified in AD model mice. The prepared PAPA/siRNA NPs exhibited a regular spherical appearance with a uniform particle size distribution profile. In in vitro cell experiments, the PAPA/siRNA NPs demonstrated excellent cellular uptake ability and efficient endosomal escape. Meanwhile, the dual-loaded siRNA nanocarrier delivery system effectively inhibited the expression of GSK3β and BACE1 genes. In vivo experimental results showed that the siRNA could successfully cross the BBB and deliver to the brain. It not only significantly prolonged the half-life of siRNA but also greatly reduced the generation of pathological β-amyloid and phosphorylated microtubule-associated protein tau, showing excellent therapeutic effects in the treatment of AD. In this study, we successfully constructed a brain-targeted siRNA nanocarrier delivery system for double-gene knockdown. This system can efficiently overcome the obstacle of the BBB, markedly alleviating cognitive and memory deficits in AD mice. It paves the way for novel strategies in the clinical treatment of AD and is expected to bring new breakthroughs and changes to the conquest of this disease. Show less
no PDF DOI: 10.1111/1440-1681.70108
APOE
Wenjie Li, Chen Li, Xing Li +1 more · 2026 · The aging male : the official journal of the International Society for the Study of the Aging Male · Taylor & Francis · added 2026-04-24
Prostate cancer (PCa) is a leading cause of male cancer-related death globally. While the gut microbiota is linked to PCa, its genetic association remains unclear. We screened genetic instruments rela Show more
Prostate cancer (PCa) is a leading cause of male cancer-related death globally. While the gut microbiota is linked to PCa, its genetic association remains unclear. We screened genetic instruments related to the gut microbiota and paired them with PCa genome-wide association study data to conduct Mendelian randomization (MR) analysis. Positive MR findings were then subjected to colocalization analysis. Subsequently, we utilized the Gene Expression Omnibus (GEO) dataset to perform differential expression analysis, aiming to identify differentially expressed associated genes (DEAGs). We determined the importance scores of these DEAGs through four machine learning models and constructed a nomogram based on these findings, and then validated it in another group of the GEO dataset. MR analysis found 16 gut bacteria causally linked to PCa (7 risk, 9 protective), with 144 related genes. PLCL1, VSNL1, ROR2, NRXN3, and TEAD1 were identified as feature genes for constructing a nomogram that provides a quantitative prediction of the risk of PCa onset. This study indicates that there are causal links between the gut microbiota and PCa. Feature genes may affect the occurrence of PCa by inhibiting the epithelial-mesenchymal transition, proliferation, migration, and invasion of cells. Show less
no PDF DOI: 10.1080/13685538.2026.2615561
NRXN3
Jingran Yang, Fang Ma, Yu Wang +7 more · 2026 · BMC public health · BioMed Central · added 2026-04-24
Parents of children with congenital heart disease (CHD) face chronic stress impairing family functioning and well-being. As a key protective factor, family resilience aids their adaptation. However, e Show more
Parents of children with congenital heart disease (CHD) face chronic stress impairing family functioning and well-being. As a key protective factor, family resilience aids their adaptation. However, existing research predominantly measures general family resilience, neglecting heterogeneous resilience patterns and subgroup profiles. Our study uses person-centered Latent Profile Analysis (LPA) to identify latent family resilience classes in Chinese culture to provide tailored support. This study adopted a cross-sectional survey design. From October 2024 to July 2025, convenience sampling was used to recruit 426 eligible parents of children with CHD from two tertiary hospitals in Yunnan Province, China. Data were collected using the General Information Questionnaire, Family Hardiness Index (FHI), Simplified Coping Style Questionnaire (SCSQ), and Social Support Rating Scale (SSRS). LPA was applied to classify the family resilience levels of these parents. Subsequently, univariate and multivariate ordinal logistic regression analyses were conducted to explore the factors associated with different latent classes of family resilience. A total of 400 valid questionnaires were collected, with an effective response rate of 93.9%. The mean total score for family resilience in parents of children with CHD was 58.13 ± 5.79, suggesting a moderate overall level of family resilience in this group. The family resilience of parents of children with CHD was classified into three latent profiles: “High family resilience responsibility-anchored type” ( Parents of children with CHD demonstrate heterogeneity in family resilience. Healthcare professionals should pay attention to the family resilience differences among parents of children with CHD and implement targeted intervention measures based on the characteristics of different subgroups, thereby enhancing parents’ family resilience and further promoting family well-being. The online version contains supplementary material available at 10.1186/s12889-025-26143-0. Show less
📄 PDF DOI: 10.1186/s12889-025-26143-0
LPA
Yajie Zang, Hui Zhang, Zheng Ruan +6 more · 2026 · European neurology · added 2026-04-24
Brain-derived neurotrophic factor (BDNF) plays an important role in the survival of dopaminergic neurons. Clinical studies have suggested that serum BDNF levels are reduced in patients with Parkinson' Show more
Brain-derived neurotrophic factor (BDNF) plays an important role in the survival of dopaminergic neurons. Clinical studies have suggested that serum BDNF levels are reduced in patients with Parkinson's disease (PD). However, no study has investigated peripheral BDNF levels and BDNF Val66Met polymorphism in the prodromal stage of PD and their relationship with disease conversion. In total, 120 patients with video-polysomnography confirmed isolated REM sleep behavior disorder (iRBD) and 120 healthy controls (HCs) were enrolled. Genetic analyses were performed, and plasma levels of BDNF were measured. All patients with iRBD underwent comprehensive clinical testing, and 107 iRBD patients were prospectively followed up. Plasma BDNF levels were significantly lower in the iRBD group than in HCs (18,878.85 pg/mL vs. 24,649.85 pg/mL, p = 0.002), but no differences were observed in BDNF Val66Met carrier rates between the two groups. Plasma BDNF levels did not differ significantly between BDNF Val66Met carriers and noncarriers. Notably, higher plasma BDNF levels were associated with an increased risk of short-term disease conversion (hazard ratio = 3.418, 95% CI: 1.520-7.684, p = 0.003), whereas BDNF Val66Met carrier rates showed no such association. Our findings suggest that plasma BDNF is significantly associated with iRBD and may likely serve as a prognostic biomarker for the development of neurodegenerative disease. However, the BDNF Val66Met polymorphism may not be involved in the pathogenesis of iRBD as well as phenoconversion in the studied population. Show less
no PDF DOI: 10.1159/000550711
BDNF bdnf dopaminergic neurons neurotrophic factor parkinson's disease rem sleep behavior disorder val66met polymorphism
Yufei Han, Yixue Zhao, Zihao Zhou +8 more · 2026 · BMC medicine · BioMed Central · added 2026-04-24
Ischemic heart failure (IHF) is one of the leading causes of death in the world. Plasma apolipoprotein C3 (ApoC3) levels are significantly elevated in patients with heart failure and positively associ Show more
Ischemic heart failure (IHF) is one of the leading causes of death in the world. Plasma apolipoprotein C3 (ApoC3) levels are significantly elevated in patients with heart failure and positively associated with the incidence of ischemic heart disease (IHD). However, the causal association between ApoC3 and IHD development is unclear. ApoC3 expression changes were assessed in plasma from IHF patients/healthy donors and cardiac tissue from rodent models. 10-week-old male human ApoC3 transgenic (ApoC3 Overexpression of human ApoC3 in ApoC3 ApoC3 overexpression could activate cardiac TLR2/NF-κB to trigger the inflammation, oxidation, and apoptosis pathways, finally aggravating IHF in mice. Inactivation of ApoC3 could significantly alleviate IHF in hamsters. Show less
no PDF DOI: 10.1186/s12916-026-04855-3
APOC3
Ling-Rong Xiao, Si-Jin Liu, Jun-Ru Li +6 more · 2026 · Child: care, health and development · Blackwell Publishing · added 2026-04-24
Families with children diagnosed with autism spectrum disorder (ASD) often encounter significant challenges, manifesting in elevated stress levels and compromised physical and mental well-being. This Show more
Families with children diagnosed with autism spectrum disorder (ASD) often encounter significant challenges, manifesting in elevated stress levels and compromised physical and mental well-being. This study employed Latent Profile Analysis (LPA) to comprehensively examine family resilience attributes among 328 Chinese parents of children with ASD. Drawing on Walsh's family resilience framework and the Double ABCX stress-adaptation model, the research examined how protective factors (social support, posttraumatic growth) and risk factors (family stressors) distinctively characterize resilience profiles and predict profile membership, alongside sociodemographic correlates. Through rigorous statistical analysis, the following three distinct family resilience profiles emerged: adversity (32.31%; characterized by low resilience), ordinary (46.65%; demonstrating moderate resilience) and growth (21.03%; exhibiting high resilience). Critically, the findings revealed that higher family income, perceived social support and posttraumatic growth were associated with higher family resilience, while family stressors were associated with lower family resilience. These insights underscore the importance of developing targeted, personalized intervention strategies that can effectively enhance familial coping mechanisms and psychological adaptation for families navigating the complex challenges of ASD. Show less
no PDF DOI: 10.1111/cch.70222
LPA
Ling Wang, Yujie Liu, Fei Li +4 more · 2026 · Annals of clinical and translational neurology · Wiley · added 2026-04-24
Alzheimer's disease (AD) is characterized by amyloid-beta plaques, tau tangles, and neuroinflammation. C-X3-C motif chemokine ligand 1 (CX3CL1, also known as fractalkine), a neuroimmune chemokine impl Show more
Alzheimer's disease (AD) is characterized by amyloid-beta plaques, tau tangles, and neuroinflammation. C-X3-C motif chemokine ligand 1 (CX3CL1, also known as fractalkine), a neuroimmune chemokine implicated in AD pathogenesis, shows inconsistent alterations in plasma/serum across studies. Specifically examining age-dependency and diagnostic utility, we investigated plasma CX3CL1 levels across the cognitive continuum (cognitively normal [CN], amnestic mild cognitive impairment [aMCI], AD) in a Chinese cohort. A total of 443 participants, including 130 patients with AD, 72 patients with aMCI, and 99 age-and sex-matched CN controls, as well as a cohort of 142 CN subjects of different ages, were enrolled from Chongqing General Hospital. Plasma CX3CL1 levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA). Apolipoprotein E genotypes (APOE) were performed. The correlations between Plasma CX3CL1 levels and cognition test scores or age were analyzed. The optimal diagnostic sensitivity and specificity were determined using receiver operating characteristic curve analysis. Plasma CX3CL1 levels significantly increased with age in CN individuals. No significant sex difference was found. Plasma CX3CL1 levels did not differ significantly between APOE ε4 carriers and non-carriers. Stepwise elevation across continuum: CX3CL1 levels showed a significant stepwise increase: CN controls (1.73 ± 0.51 ng/mL) < aMCI (2.40 ± 1.06 ng/mL) < AD (4.15 ± 1.24 ng/mL) (p < 0.001 between all groups). This pattern persisted in both male and female subgroups, between the AD group and the aMCI group, between the AD group and the CN control group (p < 0.001), between the aMCI group and the CN control group, and between the male and female subgroups (p < 0.05). CX3CL1 levels negatively correlated with Mini-Mental State Examination (MMSE) scores and positively correlated with age. Plasma CX3CL1 levels exhibit a significant age-dependent increase in cognitively normal individuals, peak in midlife (40-49 years), and demonstrate a stepwise elevation across the AD continuum (CN → aMCI → AD). Strong inverse correlations with cognitive scores in disease groups and high diagnostic accuracy for AD, particularly against CN, support its role as a biomarker reflecting both physiological aging and AD-related pathological decline. Its regulation appears independent of APOE ε4 status. The midlife peak suggests potential relevance for preclinical processes, warranting further investigation of CX3CL1 as a biomarker and therapeutic target. Show less
no PDF DOI: 10.1002/acn3.70320
APOE